Companies Omnicell, Inc
Omnicell (OMCL): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Omnicell, Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers26th pct.Of 20 peer CEOs
CEO pay, last three years
- $11,022,072FY2023
- $8,174,639FY2024
- $7,531,852FY2025
CEO total pay was $7,531,852 in fiscal 2025, down from $8,174,639 in fiscal 2024.
FY2025: salary $846,891 · bonus $0 · stock awards $5,219,576 · option awards $0
Executives and directors
H. Baird Radford · CFORandall Lipps · CEONchacha Etta · CFONnamdi Njoku · COOCorey Manley · General CounselBruce E. Scott · Independent DirectorEdward P. Bousa · Independent DirectorEileen J. Voynick · Independent DirectorJoanne B. Bauer · Independent DirectorKaushik Bobby Ghoshal · Independent DirectorMark W. Parrish · Independent DirectorMary A. Garrett · Independent DirectorRobin G. Seim · Lead Independent Director
Frequently asked questions
Who was the highest-paid executive at Omnicell, Inc in fiscal 2025?
As disclosed, Randall Lipps (Chairman, President and Chief Executive Officer) was the highest-paid executive at Omnicell, Inc in fiscal 2025, with total compensation of $7,531,852.
How does Omnicell, Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Randall Lipps's total compensation ranked at the 26th percentile of Omnicell, Inc's disclosed peer group.
What is Omnicell, Inc's CEO-to-median employee pay ratio?
As disclosed, Omnicell, Inc's CEO-to-median employee pay ratio was 70:1.
How did shareholders vote on Omnicell, Inc's executive compensation?
As disclosed, 96.02% of shareholders supported Omnicell, Inc's executive compensation in the latest say-on-pay vote.
How much does Omnicell, Inc spend in total on board compensation for fiscal 2025?
As disclosed, Omnicell, Inc reported total board compensation of $2,576,796 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Randall Lipps | $846,891 | $0 | $5,219,576 | $0 | $1,411,485 | $0 | $53,900 | $7,531,852 |
| Chairman, President and Chief Executive Officer | ||||||||
| Nnamdi Njoku | 645,000 | 0 | 2,456,275 | — | 860,000 | 0 | 43,839 | 4,005,114 |
| Executive Vice President, Chief Operating Officer | ||||||||
| Corey Manley | 416,623 | — | 1,473,739 | 0 | 499,948 | 0 | 65,700 | 2,456,010 |
| Executive Vice President, Chief Legal and Administrative Officer | ||||||||
| Nchacha Etta | 449,423 | 0 | 0 | — | 539,308 | 0 | 996,427 | 1,985,158 |
| Former Executive Vice President, Chief Financial Officer | ||||||||
| H. Baird Radford | 159,519 | 0 | 1,156,572 | — | 191,423 | 0 | 6,000 | 1,513,514 |
| Executive Vice President, Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Randall Lipps | $7,531,852 | $8,174,639 | $11,022,072 | ↓ −642,787 |
| Nnamdi Njoku | 4,005,114 | 2,737,159 | — | ↑ +1,267,955 |
| Corey Manley | 2,456,010 | 2,715,218 | 3,057,846 | ↓ −259,208 |
| Nchacha Etta | 1,985,158 | 3,138,838 | 5,158,445 | ↓ −1,153,680 |
| H. Baird Radford | 1,513,514 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to provide our executive officers incentives and rewards, while balancing the short-term and long-term interests of our stockholders with our ability to attract and retain talented executives.
| CEO STI target (% of salary) | 125% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Exequity |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Corey Manley | PSU | 2025-03-15 | 11,223 | 22,445 | — | 44,890 | $733,054 |
| Nnamdi Njoku | PSU | 2025-03-15 | 18,705 | 37,409 | — | 74,818 | 1,221,778 |
| Corey Manley | RSU | 2025-03-15 | — | — | 22,445 | — | 740,685 |
| H. Baird Radford | RSU | 2025-11-15 | — | — | 32,932 | — | 1,156,572 |
| Randall Lipps | PSU | 2025-03-15 | 39,747 | 79,494 | — | 158,988 | 2,596,274 |
| Randall Lipps | RSU | 2025-03-15 | — | — | 79,494 | — | 2,623,302 |
| Nnamdi Njoku | RSU | 2025-03-15 | — | — | 37,409 | — | 1,234,497 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Corey Manley | $740,685 | $733,054 | $0 | 49.7% |
| Nnamdi Njoku | 1,234,497 | 1,221,778 | 0 | 49.7% |
| H. Baird Radford | 1,156,572 | 0 | 0 | 0.0% |
| Randall Lipps | 2,623,302 | 2,596,274 | 0 | 49.7% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Corey Manley | RSU | 3,750 | — | $169,875 |
| Nchacha Etta | RSU | 9,463 | — | 428,674 |
| Randall Lipps | RSU | 14,688 | — | 665,366 |
| Nchacha Etta | RSU | 16,657 | — | 754,562 |
| Corey Manley | RSU | 17,980 | — | 814,494 |
| Corey Manley | RSU | 22,445 | — | 1,016,759 |
| Corey Manley | RSU | 31,649 | — | 1,433,700 |
| H. Baird Radford | RSU | 32,932 | — | 1,491,820 |
| Nnamdi Njoku | RSU | 37,409 | — | 1,694,628 |
| Nnamdi Njoku | RSU | 40,140 | — | 1,818,342 |
| Corey Manley | PSU | 44,890 | — | 2,033,517 |
| Randall Lipps | RSU | 60,329 | — | 2,732,904 |
| Nnamdi Njoku | PSU | 74,818 | — | 3,389,256 |
| Randall Lipps | RSU | 79,494 | — | 3,601,078 |
| Randall Lipps | RSU | 106,196 | — | 4,810,679 |
| Randall Lipps | PSU | 158,988 | — | 7,202,156 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Joanne B. BauerIndependent · Compensation | $140,000 | $215,141 | $0 | $0 | $0 | $355,141 |
| Mary A. GarrettIndependent · Compensation (Chair) · Corporate Governance (1) | 115,000 | 215,141 | 0 | 0 | 0 | 330,141 |
| Bruce E. ScottIndependent | 117,250 | 208,399 | 0 | 0 | 0 | 325,649 |
| Robin G. SeimIndependent · Lead Independent Director | 116,250 | 207,366 | 0 | 0 | 0 | 323,616 |
| Mark W. ParrishIndependent · Audit (1) · Compensation | 115,000 | 207,366 | 0 | 0 | 0 | 322,366 |
| Eileen J. VoynickIndependent | 113,750 | 204,755 | 0 | 0 | 0 | 318,505 |
| Edward P. BousaIndependent | 106,250 | 196,980 | 0 | 0 | 0 | 303,230 |
| Kaushik Bobby GhoshalIndependent | 103,750 | 194,398 | 0 | 0 | 0 | 298,148 |
| Randall A. LippsEmployee director · Board Chair | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $27,500 |
|---|---|
| Annual equity retainer | $180,000 |
| Per board meeting fee | $27,500 |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 11,000 |
| Stock ownership guideline | $137,500 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $927,250 |
| Equity awards (grant-date value) | $1,649,546 |
| All other compensation | $0 |
| Total cost of the board | $2,576,796 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Omnicell as a peer
Companies that benchmark against OMCL
10 companies name OMCL as a compensation peer
The list of companies that name OMCL as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
MultiPlan, Inc.LIVN LivaNova PLCGMED Globus Medical, IncGDRX GoodRx Holdings, Inc.ICUI ICU Medical, Inc.MASI Masimo Corp.HAE Haemonetics CorporationAVNS Avanos Medical, Inc.PEGA Pegasystems Inc.BLKB Blackbaud IncTNDM Tandem Diabetes Care, Inc.IART Integra LifeSciences Holdings CorporationACIW ACI Worldwide, Inc.HQY HealthEquity, Inc.NTNX Nutanix, Inc.CNMD CONMED CorporationINSP Inspire Medical Systems, Inc.OFIX Orthofix Medical Inc.EVH Evolent Health, Inc.ITGR Integer Holdings Corporation
Peer reciprocity
Of the companies Omnicell, Inc names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
— LivaNova PLC (LIVN)70 Globus Medical, Inc (GMED)— GoodRx Holdings, Inc. (GDRX)71— ICU Medical, Inc. (ICUI)72— Masimo Corp. (MASI)73— Haemonetics Corporation (HAE)74— Avanos Medical, Inc. (AVNS)75— Pegasystems Inc. (PEGA)76— Blackbaud Inc (BLKB)77— Tandem Diabetes Care, Inc. (TNDM)78— Integra LifeSciences Holdings Corporation (IART)79 ACI Worldwide, Inc. (ACIW)✓ HealthEquity, Inc. (HQY)80— Nutanix, Inc. (NTNX)81— CONMED Corporation (CNMD)82— Inspire Medical Systems, Inc. (INSP)83— Orthofix Medical Inc. (OFIX)84✓ Evolent Health, Inc. (EVH)85— Integer Holdings Corporation (ITGR)86
Reciprocity shown where the peer’s own current proxy has been read — each mark is cited in the register to that peer’s filing. A dash means the peer’s current proxy was read and names no reciprocal group including Omnicell, Inc.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Nutanix, Inc. | 2026 | Rajiv Ramaswami | $800,000 | $27,883,613 | $0 | $797,600 | $29,485,213 |
| 2 | GoodRx Holdings, Inc. | 2025 | Wendy Barnes | 825,000 | 10,921,182 | 9,000,000 | 0 | 23,367,483 |
| 3 | Masimo Corp. | 2025 | Catherine Szyman | 850,048 | 16,388,693 | 1,399,998 | 1,130,000 | 19,797,140 |
| 4 | ACI Worldwide, Inc. | 2025 | Thomas Warsop III | 750,000 | 13,204,027 | 0 | 1,018,875 | 14,999,961 |
| 5 | Evolent Health, Inc. | 2025 | Seth Blackley | 867,068 | 12,699,086 | 0 | 0 | 14,240,154 |
| 6 | HealthEquity, Inc. | 2026 | Scott Cutler | 775,000 | 12,038,563 | 0 | 767,250 | 13,582,105 |
| 7 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 8 | Avanos Medical, Inc. | 2025 | David Pacitti | 751,705 | 7,000,000 | 0 | 1,148,667 | 9,469,803 |
| 9 | Integra LifeSciences Holdings Corporation | 2025 | Mojdeh Poul | 1,009,616 | 5,219,868 | 2,250,011 | 174,563 | 9,375,551 |
| 10 | Integer Holdings Corporation | 2025 | Joseph Dziedzic | 1,235,000 | 5,999,951 | 0 | 1,323,766 | 8,671,332 |
| 11 | Pegasystems Inc. | 2025 | Alan Trefler | 600,000 | 0 | 7,001,532 | 720,000 | 8,332,032 |
| 12 | LivaNova PLC | 2025 | Vladimir Makatsaria | 956,115 | 4,303,092 | 1,374,999 | 1,287,656 | 8,047,217 |
| 13 | Inspire Medical Systems, Inc. | 2025 | Timothy Herbert | 750,572 | 5,999,655 | 0 | 961,557 | 7,711,784 |
| 14 | Conmed Corporation | 2025 | Patrick Beyer | 891,100 | 2,499,971 | 2,499,977 | 1,129,469 | 7,634,873 |
| 15 | Omnicell, Inc | 2025 | Randall Lipps | 846,891 | 5,219,576 | 0 | 1,411,485 | 7,531,852 |
| 16 | Orthofix Medical Inc. | 2025 | Massimo Calafiore | 848,322 | 4,499,988 | 1,500,009 | 445,579 | 7,310,039 |
| 17 | Tandem Diabetes Care, Inc. | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 18 | ICU Medical, Inc. | 2025 | Vivek Jain | 775,000 | 4,500,023 | 0 | 1,162,500 | 6,452,042 |
| 19 | Blackbaud Inc | 2025 | Michael Gianoni | 800,031 | 5,206,285 | 0 | 0 | 6,022,250 |
| 20 | Globus Medical, Inc | 2025 | Keith Pfeil | 479,467 | 0 | 2,982,347 | 783,000 | 4,400,159 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Omnicell, Inc | 133.3% | RSU 50 · PSU 50 | No | Exequity |
| ACI Worldwide, Inc. | 135.85% | PSU 65 · RSU 35 | No | Compensia, Inc. |
| Avanos Medical, Inc. | 139% | PSU 50 · RSU 25 · Options 25 | No | Meridian Compensation Partners |
| Blackbaud Inc | not disclosed | RSA or RSU 50 · PRSU 50 | No | Compensia, Inc. |
| Conmed Corporation | 126.8% | Options 50 · PSU 50 | Yes — rTSR | Compensia, Inc. |
| Evolent Health, Inc. | 75% | PSU 70 · RSU 30 | No | Exequity |
| Globus Medical, Inc | 102% | Options 100 | not disclosed | FW Cook |
| GoodRx Holdings, Inc. | not disclosed | not disclosed | not disclosed | Pay Governance |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| HealthEquity, Inc. | 99% | PSU 60 · RSU 40 | Yes | Semler Brossy |
| ICU Medical, Inc. | 150% | PSU 50 · RSU 50 | No | Compensia |
| Inspire Medical Systems, Inc. | 111.4% | PSU 50 · RSU 50 | No | Aon |
| Integer Holdings Corporation | 85.75% | PSU 66 · RSU 34 | Yes — Relative TSR versus peer group | FW Cook |
| Integra LifeSciences Holdings Corporation | 40% | PSU 50 · Options 25 · RSU 25 | No | WTW |
| LivaNova PLC | 122.4% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Masimo Corp. | not disclosed | not disclosed | not disclosed | FW Cook |
| Nutanix, Inc. | 99.7% | RSU 50 · PSU 50 | Yes — Relative TSR vs Nasdaq Composite Index | Compensia |
| Orthofix Medical Inc. | 47.7% | PSU 50 · Option 25 · RSU 25 | No | Meridian |
| Pegasystems Inc. | 120% | not disclosed | No | not disclosed |
| Tandem Diabetes Care, Inc. | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-19 | 35,277,398 | 1,461,980 | 16,442 | 96.02% | Passed |
| 2025 | 2025-05-21 | 35,780,985 | 1,724,508 | 180,671 | 95.4% | Passed |
| 2024 | 2024-05-21 | 36,936,934 | 2,652,637 | 121,211 | 93.3% | Passed |
| 2023 | 2023-05-23 | 36,372,761 | 3,621,541 | 36,343 | 90.94% | Passed |
| 2022 | 2022-05-24 | 37,148,931 | 2,106,001 | 54,571 | 94.64% | Passed |
| 2021 | 2021-05-25 | 35,918,517 | 2,175,281 | 41,883 | 94.29% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-19 | 96.02%a |
| 2025 | 2025-05-21 | 95.4%b |
| 2024 | 2024-05-21 | 93.3%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 70 : 1 |
|---|---|
| CEO total compensation | $7,531,852 |
| Median employee compensation | $106,853 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Corey Manley | Evp&chief Legal/Admin Officer | 2026-05-15 | D | 4,041 | $43 | $174,248 | Common | Form 4 ↗ |
| Brian H. Nutt | VP, Chief Accounting Officer | 2026-05-15 | D | 226 | 43 | 9,745 | Common | Form 4 ↗ |
| Nnamdi Njoku | EVP, Chief Operating Officer | 2026-05-15 | D | 3,660 | 43 | 157,819 | Common | Form 4 ↗ |
| Randall A. Lipps | Director | 2026-05-15 | D | 12,347 | 43 | 532,403 | Common | Form 4 ↗ |
| Corey Manley | Evp&chief Legal/Admin Officer | 2026-05-18 | D | 5,025 | 43 | 217,181 | Common | Form 4 ↗ |
| Nnamdi Njoku | EVP, Chief Operating Officer | 2026-05-18 | D | 3,090 | 43 | 133,550 | Common | Form 4 ↗ |
| Edward P. Bousa | Director | 2026-06-01 | A | 4,603 | 0 | 0 | Common | Form 4 ↗ |
| Mary A. Garrett | Director | 2026-06-01 | A | 5,027 | 0 | 0 | Common | Form 4 ↗ |
| Kaushik Bobby Ghoshal | Director | 2026-06-01 | A | 4,603 | 0 | 0 | Common | Form 4 ↗ |
| Mark W. Parrish | Director | 2026-06-01 | A | 4,845 | 0 | 0 | Common | Form 4 ↗ |
| Joanne B. Bauer | Director | 2026-06-01 | A | 5,027 | 0 | 0 | Common | Form 4 ↗ |
| Bruce E. Scott | Director | 2026-06-01 | A | 4,627 | 0 | 0 | Common | Form 4 ↗ |
| Robin G. Seim | Director | 2026-06-01 | A | 4,845 | 0 | 0 | Common | Form 4 ↗ |
| Eileen J. Voynick | Director | 2026-06-01 | A | 4,785 | 0 | 0 | Common | Form 4 ↗ |
| Nnamdi Njoku | President & COO | 2026-07-01 | A | 12,309 | 0 | 0 | Common | Form 4 ↗ |
| Randall A. Lipps | Director | 2026-07-15 | D | 10,000 | 47 | 470,000 | Common | Form 4 ↗ |
| Randall A. Lipps | Director | 2026-08-15 | D | 12,350 | 37 | 460,655 | Common | Form 4 ↗ |
| Nnamdi Njoku | President & COO | 2026-08-15 | D | 3,670 | 37 | 136,891 | Common | Form 4 ↗ |
| Brian H. Nutt | VP, Chief Accounting Officer | 2026-08-15 | D | 937 | 37 | 34,950 | Common | Form 4 ↗ |
| Corey Manley | Evp&chief Legal/Admin Officer | 2026-08-15 | D | 4,025 | 37 | 150,133 | Common | Form 4 ↗ |
| Nnamdi Njoku | President & COO | 2026-08-17 | D | 3,083 | 37 | 113,609 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (86 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Randall Lipps. DEF 14A, filed 2026-04-13. Section “2025 SUMMARY COMPENSATION TABLE” · page 42. As printed: 7,531,852. View filing ↗
- Section 01, Nnamdi Njoku. DEF 14A, filed 2026-04-13. Section “2025 SUMMARY COMPENSATION TABLE” · page 42. As printed: 4,005,114. View filing ↗
- Section 01, Corey Manley. DEF 14A, filed 2026-04-13. Section “2025 SUMMARY COMPENSATION TABLE” · page 42. As printed: 2,456,010. View filing ↗
- Section 01, Nchacha Etta. DEF 14A, filed 2026-04-13. Section “2025 SUMMARY COMPENSATION TABLE” · page 42. As printed: 1,985,158. View filing ↗
- Section 01, H. Baird Radford. DEF 14A, filed 2026-04-13. Section “2025 SUMMARY COMPENSATION TABLE” · page 42. As printed: 1,513,514. View filing ↗
- Section 03, Corey Manley PSU. DEF 14A, filed 2026-04-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Nnamdi Njoku PSU. DEF 14A, filed 2026-04-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Corey Manley RSU. DEF 14A, filed 2026-04-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, H. Baird Radford RSU. DEF 14A, filed 2026-04-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Randall Lipps PSU. DEF 14A, filed 2026-04-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Randall Lipps RSU. DEF 14A, filed 2026-04-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Nnamdi Njoku RSU. DEF 14A, filed 2026-04-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-13. Section “CEO Pay Ratio”. As printed: 70 : 1. View filing ↗
- Section 08, Joanne B. Bauer. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 355,141. View filing ↗
- Section 08, Mary A. Garrett. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 330,141. View filing ↗
- Section 08, Bruce E. Scott. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 325,649. View filing ↗
- Section 08, Robin G. Seim. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 323,616. View filing ↗
- Section 08, Mark W. Parrish. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 322,366. View filing ↗
- Section 08, Eileen J. Voynick. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 318,505. View filing ↗
- Section 08, Edward P. Bousa. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 303,230. View filing ↗
- Section 08, Kaushik Bobby Ghoshal. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 298,148. View filing ↗
- Section 08, Randall A. Lipps. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Corey Manley 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian H. Nutt 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nnamdi Njoku 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall A. Lipps 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Corey Manley 2026-05-18. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nnamdi Njoku 2026-05-18. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward P. Bousa 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary A. Garrett 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kaushik Bobby Ghoshal 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark W. Parrish 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joanne B. Bauer 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce E. Scott 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robin G. Seim 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eileen J. Voynick 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nnamdi Njoku 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall A. Lipps 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall A. Lipps 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nnamdi Njoku 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian H. Nutt 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Corey Manley 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nnamdi Njoku 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-26. Item 5.07 · say-on-pay result. As reported: 96.02% (votes for as printed: 35,277,398). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-23. Item 5.07 · say-on-pay result. As reported: 95.4% (votes for as printed: 35,780,985). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-24. Item 5.07 · say-on-pay result. As reported: 93.3% (votes for as printed: 36,936,934). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 927,250 + equity 1,649,546 + all other 0 = 2,576,796, summed across the director compensation table rows.
- Nutanix, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-20. CEO total compensation as printed in Nutanix, Inc.'s own proxy. As printed: 29,485,213. View filing ↗
- GoodRx Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in GoodRx Holdings, Inc.'s own proxy. As printed: 23,367,483. View filing ↗
- Masimo Corp., Section 10b CEO total. 10-K/A, filed 2026-05-01. CEO total compensation as printed in Masimo Corp.'s own proxy. As printed: 19,797,140. View filing ↗
- ACI Worldwide, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in ACI Worldwide, Inc.'s own proxy. As printed: 14,999,961. View filing ↗
- Evolent Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Evolent Health, Inc.'s own proxy. As printed: 14,240,154. View filing ↗
- HealthEquity, Inc., Section 10b CEO total. DEF 14A, filed 2026-05-13. CEO total compensation as printed in HealthEquity, Inc.'s own proxy. As printed: 13,582,105. View filing ↗
- Haemonetics Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-09. CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. View filing ↗
- Avanos Medical, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-12. CEO total compensation as printed in Avanos Medical, Inc.'s own proxy. As printed: 9,469,803. View filing ↗
- Integra LifeSciences Holdings Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Integra LifeSciences Holdings Corporation's own proxy. As printed: 9,375,551. View filing ↗
- Integer Holdings Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Integer Holdings Corporation's own proxy. As printed: 8,671,332. View filing ↗
- Pegasystems Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Pegasystems Inc.'s own proxy. As printed: 8,332,032. View filing ↗
- LivaNova PLC, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in LivaNova PLC's own proxy. As printed: 8,047,217. View filing ↗
- Inspire Medical Systems, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Inspire Medical Systems, Inc.'s own proxy. As printed: 7,711,784. View filing ↗
- Conmed Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Conmed Corporation's own proxy. As printed: 7,634,873. View filing ↗
- Omnicell, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Omnicell, Inc's own proxy. As printed: 7,531,852. View filing ↗
- Orthofix Medical Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Orthofix Medical Inc.'s own proxy. As printed: 7,310,039. View filing ↗
- Tandem Diabetes Care, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Tandem Diabetes Care, Inc.'s own proxy. As printed: 6,858,503. View filing ↗
- ICU Medical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in ICU Medical, Inc.'s own proxy. As printed: 6,452,042. View filing ↗
- Blackbaud Inc, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Blackbaud Inc's own proxy. As printed: 6,022,250. View filing ↗
- Globus Medical, Inc, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Globus Medical, Inc's own proxy. As printed: 4,400,159. View filing ↗
- Section 10a, LivaNova PLC reciprocity. DEF 14A. LivaNova PLC's most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗
- Section 10a, GoodRx Holdings, Inc. reciprocity. DEF 14A. GoodRx Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗
- Section 10a, ICU Medical, Inc. reciprocity. DEF 14A. ICU Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗
- Section 10a, Masimo Corp. reciprocity. DEF 14A. Masimo Corp.'s most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗
- Section 10a, Haemonetics Corporation reciprocity. DEF 14A. Haemonetics Corporation's most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗
- Section 10a, Avanos Medical, Inc. reciprocity. DEF 14A. Avanos Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗
- Section 10a, Pegasystems Inc. reciprocity. DEF 14A. Pegasystems Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗
- Section 10a, Blackbaud Inc reciprocity. DEF 14A. Blackbaud Inc's most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗
- Section 10a, Tandem Diabetes Care, Inc. reciprocity. DEF 14A. Tandem Diabetes Care, Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗
- Section 10a, Integra LifeSciences Holdings Corporation reciprocity. DEF 14A. Integra LifeSciences Holdings Corporation's most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗
- Section 10a, HealthEquity, Inc. reciprocity. DEF 14A. HealthEquity, Inc. names Omnicell, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Nutanix, Inc. reciprocity. DEF 14A. Nutanix, Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗
- Section 10a, CONMED Corporation reciprocity. DEF 14A. CONMED Corporation's most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗
- Section 10a, Inspire Medical Systems, Inc. reciprocity. DEF 14A. Inspire Medical Systems, Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗
- Section 10a, Orthofix Medical Inc. reciprocity. DEF 14A. Orthofix Medical Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗
- Section 10a, Evolent Health, Inc. reciprocity. DEF 14A. Evolent Health, Inc. names Omnicell, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Integer Holdings Corporation reciprocity. DEF 14A. Integer Holdings Corporation's most recent proxy was read; its disclosed peer group does not include Omnicell, Inc. View filing ↗